• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

FDA Selects Aetion Evidence Platform to Assess In-Patient COVID-19 Treatments

by Jasmine Pennic 10/21/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Syneos Health, Aetion Partner to Offer RWE Solutions to Advance Drug Development and Commercialization

What You Should Know:

– Aetion, a NYC-based leading real-world evidence (RWE) company,  announced that the U.S. Food and Drug Administration (FDA) has contracted with them to use their Aetion Evidence Platform® to rapidly assess in-patient COVID-19 treatments and advance regulatory science to help determine when, where and how to use RWD.

– This project is designed to demonstrate how using a platform-based approach furthers regulatory learnings on the use of RWE to inform decision-making. The work will also provide a scalable infrastructure for the rapid development and evaluation of COVID-19 therapies, which can be applied for future public health emergencies.

Enables rapid evidence generation for COVID-19 and future pandemics

The aim of this project is to further data familiarity and protocol standards to support real-world data (RWD) analyses among the broader research community. FDA will work with Aetion to define and prioritize key research questions; identify fit-for-purpose data sources; develop appropriate, validated, and applicable measurement algorithms to capture key exposures, subgroups, confounding variables, and outcomes; design template epidemiological studies applicable to a range of treatments; implement studies and generate transparent reporting using AEP; and build and disseminate knowledge via peer-reviewed publications and other avenues.

Aetion and FDA will build on learnings from the research collaboration announced in May 2020, in which FDA and Aetion explored the utility of RWD to advance the understanding of and response to COVID-19. Since launching the collaboration, FDA and Aetion have developed mechanisms to assess data fitness for use; identified methodological good practices on working with RWD for COVID-19; and built the foundation for rapid-cycle analytics to address critical and emergent public health questions.

“COVID-19 has created an urgent need to develop and apply innovative methods to assess novel interventions,” said Dr. Jeremy Rassen, co-founder and president of Aetion. “As FDA continues to advance its digital capabilities, Aetion is proud to partner with the agency in developing the rigorous scientific processes and RWE generation tools needed to quickly respond to future public health challenges.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Aetion, Coronavirus (COVID-19), FDA

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

How AI Helps Health Systems Improve the Quality of Care for Patients with Chronic Conditions

How AI Helps Health Systems Improve the Quality of Care for Patients with Chronic Conditions

10 Critical KPIs Every Successful Healthcare Organization is Implementing10 Critical KPIs Every Successful Healthcare Organization is Implementing

Trending

Why The Evolution of Tech Will be Based on APIs

Why The Evolution of Tech Will be Based on APIs

Podimetrics CMO Talks Supporting Patients Living with SDoH Challenges

Podimetrics Director Talks Supporting Patients Living with SDoH Challenges

: Does Alzheimer’s Cure Matter if We Don't Fix the Economic Infrastructure of the Disease?

Does Alzheimer’s Cure Matter if We Don’t Fix the Economic Infrastructure of the Disease?

Recent Digital Health Partnerships

Roundups: 15 Recent Digital Health Strategic Partnerships

Recent Digital Health Executive Hires & Board Appointments

Digital Health Executive Hires: Practice Better Appoints CEO, HHAeXchange, Intelerad, Tegria, Others

M&A: Florence Acquires Virtual Care Solution Zipnosis

M&A: Florence Acquires Virtual Care Solution Zipnosis

Adopting Value-Based Care Models for Autism Care Is Imperative

Why Adopting Value-Based Care Models for Autism Care Is Imperative

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

Vanderbilt University Medical Center Taps Philips Reduce Carbon Footprint

Vanderbilt University Medical Center Taps Philips to Reduce Carbon Footprint

Denials Management Named Most Time-Consuming Task in RCM

Denials Management Named Most Time-Consuming Task in RCM

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |